Skip to main content

Guerrero Ramiro's Form 4/A amendment

Amended

MAIA Biotechnology, Inc.MAIA · filed Mar 5, 2025

Accession no.
0001127602-25-008317
Filed
Mar 5, 2025
Trade date
Feb 24, 2025
Filing delay
9 days
Rule 10b5-1 plan
Not checked
Original filed
Feb 25, 2025

This filing lists 1 non-derivative transaction and 1 derivative transaction. Open-market purchases total $110.0K. It was filed 9 days after the trade.

This amendment replaces 0001127602-25-006578 (filed Feb 25, 2025).

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Guerrero RamiroCIK 0001913253Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 24, 2025Common StockPPurchaseAcquired+73,333$1.50+$109,999.5534,885.04Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 24, 2025Common StockPPurchaseAcquired+73,333$1.87+$137,132.7173,333Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The common stock was purchased pursuant to a Securities Purchase Agreement and were issued under the Issuer's 2021 Equity Incentive Plna on February 24, 2025.

F2

This Form 4/A is being filed to correct the "Date Exercisable" and "Expiration Date" in Section 6 of Table II reported in the original Form 4 filed on February 25, 2025 as well as to correct the date of the Securities Purchase Agreement orginally referenced in the footnote 1 and 2 to "February 24, 2025".

F3

These warrants were purchased pursuant to a Securities Purchase Agreement and were deemed options issued under the Issuer's 2021 Equity Incentive Plan on February 24, 2025. The options are exercisable beginning on the one-year anniversary of the issuance date and expire 6-years after the initial issuance date.

Read the full filing on SEC EDGAR (opens in a new tab)